Symbols / ATYR $0.81 -2.05%
ATYR Chart
About
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 79.48M |
| Enterprise Value | 14.30M | Income | -74.12M | Sales | 190.00K |
| Book/sh | 0.69 | Cash/sh | 0.80 | Dividend Yield | — |
| Payout | 0.00% | Employees | 58 | IPO | — |
| P/E | — | Forward P/E | -2.02 | PEG | — |
| P/S | 418.32 | P/B | 1.18 | P/C | — |
| EV/EBITDA | -0.19 | EV/Sales | 75.27 | Quick Ratio | 5.25 |
| Current Ratio | 5.30 | Debt/Eq | 17.88 | LT Debt/Eq | — |
| EPS (ttm) | -0.80 | EPS next Y | -0.40 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-07 | ROA | -51.12% |
| ROE | -108.11% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -408.56% | Profit Margin | 0.00% | Shs Outstand | 98.05M |
| Shs Float | 95.60M | Short Float | 22.95% | Short Ratio | 7.14 |
| Short Interest | — | 52W High | 7.29 | 52W Low | 0.64 |
| Beta | 0.56 | Avg Volume | 1.86M | Volume | 475.21K |
| Target Price | $4.36 | Recom | Hold | Prev Close | $0.83 |
| Price | $0.81 | Change | -2.05% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.36
Mean price target
2. Current target
$0.81
Latest analyst target
3. DCF / Fair value
$-6.20
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.81
Low
$1.00
High
$20.00
Mean
$4.36
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-07 | main | RBC Capital | Sector Perform → Sector Perform | $1 |
| 2025-09-16 | down | Wells Fargo | Overweight → Equal-Weight | $1 |
| 2025-09-16 | down | RBC Capital | Outperform → Sector Perform | $2 |
| 2025-09-15 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2025-09-15 | down | Leerink Partners | Outperform → Market Perform | $1 |
| 2025-09-15 | down | Jones Trading | Buy → Hold | — |
| 2025-09-15 | down | Cantor Fitzgerald | Overweight → Neutral | — |
| 2025-09-15 | down | LUCID CAPITAL MARKETS | Buy → Neutral | $1 |
| 2025-08-22 | main | Jefferies | Buy → Buy | $17 |
| 2025-06-20 | main | Wells Fargo | Overweight → Overweight | $25 |
| 2025-06-04 | reit | HC Wainwright & Co. | Buy → Buy | $35 |
| 2025-05-19 | reit | HC Wainwright & Co. | Buy → Buy | $35 |
| 2025-03-14 | reit | HC Wainwright & Co. | Buy → Buy | $35 |
| 2025-02-18 | init | Leerink Partners | — → Outperform | $16 |
| 2025-01-06 | init | Cantor Fitzgerald | — → Overweight | — |
| 2024-12-10 | reit | HC Wainwright & Co. | Buy → Buy | $35 |
| 2024-12-03 | reit | HC Wainwright & Co. | Buy → Buy | $35 |
| 2024-10-29 | reit | HC Wainwright & Co. | Buy → Buy | $35 |
| 2024-10-04 | init | Wells Fargo | — → Overweight | $17 |
| 2024-09-05 | init | Jefferies | — → Buy | $9 |
- aTyr Pharma stock crashes on Phase III pulmonary sarcoidosis fail - Clinical Trials Arena ue, 16 Sep 2025 07
- Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Deliver On Growth Plans? - Yahoo Finance Sun, 11 Jan 2026 08
- Biotech aTyr gives new employees 12,200 stock options at $0.98 - Stock Titan Fri, 20 Feb 2026 08
- aTyr Pharma Insiders Added US$926.8k Of Stock To Their Holdings - simplywall.st Wed, 18 Feb 2026 08
- aTyr Pharma (NASDAQ:ATYR) Upgraded at Wall Street Zen - MarketBeat Sun, 15 Mar 2026 05
- Jefferies reiterates aTyr Pharma stock rating on regulatory outlook - Investing.com Fri, 06 Mar 2026 08
- ATyr shares plunge on trial miss in inflammatory lung disease - BioPharma Dive Mon, 15 Sep 2025 07
- aTyr flunks phase 3 lung disease trial, deflating stock, but still plans talks with FDA - Fierce Biotech Mon, 15 Sep 2025 07
- aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Fri, 20 Feb 2026 08
- After key study miss, FDA to weigh aTyr lung disease drug in April - Stock Titan hu, 05 Mar 2026 08
- Assessing aTyr Pharma (ATYR) Valuation as Investors Weigh Recent Stock Swings and Future Prospects - Yahoo Finance Wed, 17 Sep 2025 07
- Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth? - simplywall.st hu, 18 Dec 2025 08
- aTyr Pharma (NASDAQ: ATYR) asks shareholders to double authorized shares to 340M - Stock Titan hu, 12 Mar 2026 20
- Independent Director of aTyr Pharma Paul Schimmel Buys 91% More Shares - Yahoo Finance Sun, 12 Oct 2025 07
- Biotech aTyr Pharma CEO to speak at Miami global healthcare conference - Stock Titan Wed, 18 Feb 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 1558 | 1521.0 | — | Sale at price 0.98 per share. | BROADFOOT JILL MARIE | Chief Financial Officer | — | 2026-02-04 00:00:00 | D |
| 1 | 3745 | 3655.0 | — | Sale at price 0.98 per share. | SHUKLA SANJAY S | Chief Executive Officer | — | 2026-02-04 00:00:00 | D |
| 2 | 1118 | 1091.0 | — | Sale at price 0.98 per share. | DENYES NANCY | General Counsel | — | 2026-02-04 00:00:00 | D |
| 3 | 3750 | nan | — | — | BROADFOOT JILL MARIE | Chief Financial Officer | — | 2026-02-03 00:00:00 | D |
| 4 | 10375 | nan | — | — | SHUKLA SANJAY S | Chief Executive Officer | — | 2026-02-03 00:00:00 | D |
| 5 | 2687 | nan | — | — | DENYES NANCY | General Counsel | — | 2026-02-03 00:00:00 | D |
| 6 | 1000000 | 911801.0 | — | Purchase at price 0.90 - 0.94 per share. | SCHIMMEL PAUL R | Director | — | 2025-10-09 00:00:00 | I |
| 7 | 3750 | 15000.0 | — | Purchase at price 4.00 per share. | GROSS JANE A | Director | — | 2025-03-17 00:00:00 | D |
| 8 | 1254 | 4740.0 | — | Sale at price 3.78 per share. | BROADFOOT JILL MARIE | Chief Financial Officer | — | 2025-02-04 00:00:00 | D |
| 9 | 899 | 3398.0 | — | Sale at price 3.78 per share. | DENYES NANCY | General Counsel | — | 2025-02-04 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -76.07M | -66.37M | -52.18M | -44.71M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -74.12M | -64.02M | -50.39M | -45.34M |
| ReconciledDepreciation | 1.55M | 1.54M | 2.74M | 1.70M |
| EBITDA | -76.07M | -66.37M | -52.18M | -44.71M |
| EBIT | -77.63M | -67.91M | -54.92M | -46.40M |
| NormalizedIncome | -74.12M | -64.02M | -50.39M | -45.34M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -74.12M | -64.02M | -50.39M | -45.34M |
| TotalExpenses | 77.82M | 68.15M | 55.27M | 56.79M |
| TotalOperatingIncomeAsReported | -77.63M | -67.91M | -54.92M | -46.40M |
| DilutedAverageShares | 74.26M | 53.61M | 28.42M | 19.08M |
| BasicAverageShares | 74.26M | 53.61M | 28.42M | 19.08M |
| DilutedEPS | -0.86 | -0.94 | -1.60 | -1.77 |
| BasicEPS | -0.86 | -0.94 | -1.60 | -1.77 |
| DilutedNIAvailtoComStockholders | -74.12M | -64.02M | -50.39M | -45.34M |
| NetIncomeCommonStockholders | -74.12M | -64.02M | -50.39M | -45.34M |
| NetIncome | -74.12M | -64.02M | -50.39M | -45.34M |
| MinorityInterests | 5.00K | -1.00K | 8.00K | 5.00K |
| NetIncomeIncludingNoncontrollingInterests | -74.12M | -64.02M | -50.40M | -45.34M |
| NetIncomeContinuousOperations | -74.12M | -64.02M | -50.40M | -45.34M |
| PretaxIncome | -74.12M | -64.02M | -50.40M | -45.34M |
| OtherIncomeExpense | 3.50M | 3.89M | 4.52M | 1.06M |
| OtherNonOperatingIncomeExpenses | 3.50M | 3.89M | 4.52M | 1.06M |
| OperatingIncome | -77.63M | -67.91M | -54.92M | -46.40M |
| OperatingExpense | 77.82M | 68.15M | 55.27M | 56.79M |
| ResearchAndDevelopment | 60.22M | 54.37M | 42.29M | 42.81M |
| SellingGeneralAndAdministration | 17.60M | 13.78M | 12.98M | 13.98M |
| GeneralAndAdministrativeExpense | 17.60M | 13.78M | 12.98M | 13.98M |
| OtherGandA | 17.60M | 13.78M | 12.98M | 13.98M |
| TotalRevenue | 190.00K | 235.00K | 353.00K | 10.39M |
| OperatingRevenue | 190.00K | 235.00K | 353.00K | 10.39M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 98.03M | 84.04M | 63.29M | 29.50M |
| ShareIssued | 98.03M | 84.04M | 63.29M | 29.50M |
| TotalDebt | 12.03M | 13.28M | 15.10M | 11.53M |
| TangibleBookValue | 67.48M | 70.02M | 90.66M | 71.46M |
| InvestedCapital | 67.48M | 70.02M | 90.66M | 71.46M |
| WorkingCapital | 65.09M | 66.99M | 86.58M | 67.01M |
| NetTangibleAssets | 67.48M | 70.02M | 90.66M | 71.46M |
| CapitalLeaseObligations | 12.03M | 13.28M | 15.10M | 11.53M |
| CommonStockEquity | 67.48M | 70.02M | 90.66M | 71.46M |
| TotalCapitalization | 67.48M | 70.02M | 90.66M | 71.46M |
| TotalEquityGrossMinorityInterest | 67.29M | 69.83M | 90.47M | 71.28M |
| MinorityInterest | -192.00K | -187.00K | -188.00K | -180.00K |
| StockholdersEquity | 67.48M | 70.02M | 90.66M | 71.46M |
| GainsLossesNotAffectingRetainedEarnings | -8.00K | -40.00K | -74.00K | -433.00K |
| OtherEquityAdjustments | -8.00K | -40.00K | -74.00K | -433.00K |
| RetainedEarnings | -606.16M | -532.05M | -468.02M | -417.63M |
| AdditionalPaidInCapital | 673.55M | 602.02M | 558.69M | 489.50M |
| CapitalStock | 98.00K | 84.00K | 63.00K | 29.00K |
| CommonStock | 98.00K | 84.00K | 63.00K | 29.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 25.71M | 27.00M | 30.18M | 24.50M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 10.57M | 12.03M | 13.77M | 10.64M |
| LongTermDebtAndCapitalLeaseObligation | 10.57M | 12.03M | 13.77M | 10.64M |
| LongTermCapitalLeaseObligation | 10.57M | 12.03M | 13.77M | 10.64M |
| CurrentLiabilities | 15.15M | 14.97M | 16.42M | 13.86M |
| CurrentDebtAndCapitalLeaseObligation | 1.47M | 1.25M | 1.33M | 894.00K |
| CurrentCapitalLeaseObligation | 1.47M | 1.25M | 1.33M | 894.00K |
| PayablesAndAccruedExpenses | 13.68M | 13.71M | 15.09M | 12.97M |
| CurrentAccruedExpenses | 9.79M | 9.39M | 11.56M | 9.86M |
| Payables | 3.89M | 4.32M | 3.53M | 3.11M |
| AccountsPayable | 3.89M | 4.32M | 3.53M | 3.11M |
| TotalAssets | 93.00M | 96.83M | 120.65M | 95.79M |
| TotalNonCurrentAssets | 12.77M | 14.88M | 17.66M | 14.91M |
| OtherNonCurrentAssets | 2.38M | 3.02M | 3.62M | 3.36M |
| NetPPE | 10.38M | 11.86M | 14.05M | 11.56M |
| AccumulatedDepreciation | -4.83M | -4.54M | -4.62M | -6.35M |
| GrossPPE | 15.21M | 16.40M | 18.67M | 17.91M |
| Leases | 5.65M | 5.65M | 5.65M | 4.41M |
| OtherProperties | 3.56M | 4.49M | 5.84M | 5.63M |
| MachineryFurnitureEquipment | 473.00K | 440.00K | 448.00K | 620.00K |
| BuildingsAndImprovements | 5.52M | 5.82M | 6.73M | 7.25M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 80.24M | 81.95M | 102.99M | 80.87M |
| OtherCurrentAssets | 2.95M | 5.22M | ||
| PrepaidAssets | 677.00K | 8.09M | 2.39M | 2.95M |
| Receivables | 873.00K | 1.74M | 2.44M | 11.78M |
| OtherReceivables | 873.00K | 1.74M | 2.44M | 11.78M |
| CashCashEquivalentsAndShortTermInvestments | 78.69M | 72.12M | 98.17M | 66.15M |
| OtherShortTermInvestments | 67.94M | 61.07M | 75.62M | 56.16M |
| CashAndCashEquivalents | 10.74M | 11.05M | 22.54M | 9.98M |
| CashEquivalents | 7.92M | 9.58M | 21.63M | 8.59M |
| CashFinancial | 2.83M | 1.47M | 918.00K | 1.40M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -62.06M | -69.18M | -37.44M | -43.53M |
| RepaymentOfDebt | -539.00K | -497.00K | -394.00K | -66.00K |
| IssuanceOfCapitalStock | 66.42M | 40.26M | 66.52M | 5.47M |
| CapitalExpenditure | -77.00K | -65.00K | -4.21M | -1.64M |
| InterestPaidSupplementalData | 94.00K | 137.00K | 172.00K | 54.00K |
| EndCashPosition | 12.98M | 14.01M | 26.03M | 13.15M |
| BeginningCashPosition | 14.01M | 26.03M | 13.15M | 2.34M |
| ChangesInCash | -1.03M | -12.02M | 12.88M | 10.81M |
| FinancingCashFlow | 66.01M | 39.86M | 66.23M | 5.45M |
| CashFlowFromContinuingFinancingActivities | 66.01M | 39.86M | 66.23M | 5.45M |
| ProceedsFromStockOptionExercised | 127.00K | 100.00K | 105.00K | 45.00K |
| NetCommonStockIssuance | 66.42M | 40.26M | 66.52M | 5.47M |
| CommonStockIssuance | 66.42M | 40.26M | 66.52M | 5.47M |
| NetIssuancePaymentsOfDebt | -539.00K | -497.00K | -394.00K | -66.00K |
| NetLongTermDebtIssuance | -539.00K | -497.00K | -394.00K | -66.00K |
| LongTermDebtPayments | -539.00K | -497.00K | -394.00K | -66.00K |
| InvestingCashFlow | -5.05M | 17.23M | -20.13M | 47.24M |
| CashFlowFromContinuingInvestingActivities | -5.05M | 17.23M | -20.13M | 47.24M |
| NetInvestmentPurchaseAndSale | -4.99M | 17.29M | -15.93M | 48.71M |
| SaleOfInvestment | 88.46M | 86.39M | 91.05M | 90.83M |
| PurchaseOfInvestment | -93.44M | -69.10M | -106.98M | -42.12M |
| NetPPEPurchaseAndSale | -65.00K | -58.00K | -4.20M | -1.46M |
| SaleOfPPE | 12.00K | 7.00K | 15.00K | 179.00K |
| PurchaseOfPPE | -77.00K | -65.00K | -4.21M | -1.64M |
| OperatingCashFlow | -61.99M | -69.12M | -33.22M | -41.89M |
| CashFlowFromContinuingOperatingActivities | -61.99M | -69.12M | -33.22M | -41.89M |
| ChangeInWorkingCapital | 7.45M | -6.92M | 15.01M | -833.00K |
| ChangeInOtherCurrentLiabilities | -711.00K | -343.00K | 2.07M | 2.11M |
| ChangeInPayablesAndAccruedExpense | -33.00K | -1.34M | 3.26M | 6.74M |
| ChangeInPrepaidAssets | 7.33M | -5.64M | 622.00K | 2.24M |
| ChangeInReceivables | 863.00K | 402.00K | 9.05M | -11.92M |
| OtherNonCashItems | 366.00K | |||
| StockBasedCompensation | 5.00M | 2.99M | 2.60M | 2.15M |
| AmortizationOfSecurities | -1.85M | -2.71M | -3.17M | 533.00K |
| DepreciationAmortizationDepletion | 1.55M | 1.54M | 2.74M | 1.70M |
| DepreciationAndAmortization | 1.55M | 1.54M | 2.74M | 1.70M |
| Depreciation | 1.55M | 1.54M | 2.74M | 1.70M |
| OperatingGainsLosses | -12.00K | -3.00K | -6.00K | -92.00K |
| GainLossOnSaleOfPPE | -12.00K | -3.00K | -6.00K | -92.00K |
| NetIncomeFromContinuingOperations | -74.12M | -64.02M | -50.40M | -45.34M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ATYR
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|